PAIN Reports Earns Indexing in PubMed Central
Feb 5, 2018
IASP has received excellent news concerning PAIN Reports: The association’s open access journal has earned indexing in PubMed Central. This means that all articles PAIN Reports has published since its inception are now accessible and searchable in this important repository of scientific literature. It also means that pain researchers and clinicians not only will find our journal a valuable resource for exposing their work to a wide audience but also for monitoring the latest developments in their field.
This landmark achievement for IASP culminates more than a year of hard work on the part of many individuals and confirms the association’s commitment to advancing knowledge and treatment in the field of pain.
In learning of the milestone, Editor-in-Chief David Yarnitsky said, “This is a mark of trust and quality of PAIN Reports, and I am very proud of this achievement. This would not have happened without the vision of IASP leadership in establishing the journal, the substantial support of very many members of the pain research community who submitted their work to a fledgling publication, and the hard work of the section editors, editorial board members, and manuscript referees, to whom I wish to convey many thanks.”
Congratulations also are due to the publishing teams at IASP and Wolters Kluwer, who helped guide the journal’s development and ushered it through PubMed Central’s assessment process.
Since its inception in August 2017, the journal has attracted 179 submissions, 83 of which have been accepted, and 68 published in ten editions. All articles published before PubMed Central awarded indexing will be retroactively indexed.
PAIN Reports promotes a global, rapid, and readily accessible forum that advances clinical, applied, and basic research on pain. The journal publishes full-length articles as well as brief reports, reviews, meta-analyses, meeting proceedings, and selected case reports. It gives special attention to submissions reporting the results of enterprising and high-risk research and pilot studies as well as locally developed clinical guidelines from scientists and clinicians in developing countries.